TIDMXEN

RNS Number : 1178X

Xenetic Biosciences PLC

07 January 2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Xenetic Biosciences plc

(the "Company" or "Xenetic")

Rule 2.10 Announcement

In accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), the Company announces that it now has in issue a total of 408,048,487 Ordinary Shares of GBP0.005 ("Ordinary Shares"). No shares are held as treasury shares, and the total number of voting rights in the Company is 408,048,487Ordinary Shares. The International Securities Identification Number (ISIN) for the Company's Ordinary Shares is GB00B08NWV55.

Further to the announcement yesterday disclosing changes to the beneficial interests of certain directors, the following table sets out the aggregate interests of those directors including their beneficial interests as co-owners under the Company's Joint Share Ownership Plan ("JSOP"):

 
                                % of                % of issued 
                              issued                      share 
                 M. Scott      share                    capital 
                  Maguire    capital   Colin Hill 
 Shares         1,426,361       0.35    1,875,420          0.46 
 JSOP June 
  2010 (1)      3,857,084       0.95    1,461,394          0.36 
 JSOP March 
  2012 (2)     23,380,673       5.73    4,701,454          1.15 
               28,664,118       7.03    8,038,268          1.97

(1) These JSOP awards are fully vested

(2) These JSOP awards are unvested.

Further information regarding the vesting of JSOP awards is available in the Scheme Document published on the Company's website at www.xeneticbio.com.

Enquiries:

   Xenetic Biosciences plc                                                       www.xeneticbio.com

M. Scott Maguire, Chief Executive Officer +44 (0)20 3021 1500

   Colin Hill, Chief Financial Officer                                           +44 (0)20 3021 1500

London Bridge Capital (Financial Adviser to Xenetic)

Adam Hart +44 (0)7912 201639

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell +44 (0)20 7496 3000

Walbrook PR +44 (0)20 7933 8780

   Mike Wort (Media Enquiries)                                 mike.wort@walbrookpr.com 
   Paul Cornelius (Investor Enquiries)                         paul.cornelius@walbrookir.com

Disclosure requirements under the Code

Under Rule 8.3(a) of the City Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which any paper offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company; and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the Offer Period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the City Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0) 20 7638 0129.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RTTUBUNRSKAARAR

Xenetic Bio (LSE:XEN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Xenetic Bio Charts.
Xenetic Bio (LSE:XEN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Xenetic Bio Charts.